Last reviewed 2026-04-23 · How we verify

Ethyl-EPA (Miraxion™)

Ethyl-EPA is an ethyl ester of eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism through omega-3 fatty acid supplementation.

Ethyl-EPA is an ethyl ester of eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism through omega-3 fatty acid supplementation. Used for Hypertriglyceridemia (elevated triglycerides), Cardiovascular risk reduction in patients with elevated triglycerides.

At a glance

Mechanism of action

Ethyl-EPA is a highly purified, prescription-grade omega-3 fatty acid (EPA ethyl ester) that works by increasing circulating EPA levels to reduce triglyceride synthesis in the liver and promote triglyceride clearance. It may also have anti-inflammatory and cardioprotective effects through modulation of lipid mediators and reduction of systemic inflammation.

Approved indications

• Hypertriglyceridemia (elevated triglycerides)
• Cardiovascular risk reduction in patients with elevated triglycerides

Common side effects

• Gastrointestinal upset
• Fishy aftertaste
• Nausea
• Diarrhea

Key clinical trials

• Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®) (PHASE1)
• TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Ethyl-EPA (Miraxion™) CI brief — competitive landscape report
• Ethyl-EPA (Miraxion™) updates RSS · CI watch RSS
• Amarin Neuroscience Ltd portfolio CI